| Filed On | Filing |
|---|---|
| 12 Nov 2026 | 10-Q |
| 12 Nov 2026 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +3 more
Third quarter 2026 revenue of $44.6 million; adjusted EBITDA loss of approximately $0.4 million, within the Company’s guidance range of negative $1 million to positive $2 million. |
| 09 Nov 2026 | NT 10-Q |
| 07 Oct 2026 | SCHEDULE 13G/A |
| 25 Sep 2026 | S-8 |
| 15 Sep 2026 |
8-K: Regulation FD Disclosure
Through an exclusive collaboration with LifeMD, eligible AT&T wireless and fiber customers receive a complimentary LifeMD membership, a $228 annual value, with on-demand access to a nationwide virtual care and pharmacy platform. |
| 18 Aug 2026 |
Form 4: Larovere Joan, Director
Received 35,000 shares as a grant or award |
| 18 Aug 2026 |
Form 4: Strawn John R Jr, Director
Received 50,000 shares as a grant or award · Received 35,000 shares as a grant or award |
| 13 Aug 2026 |
Form 4: DiTrolio Joseph, Director
Received 35,000 shares as a grant or award |
| 13 Aug 2026 |
Form 4/A: Simon Roberto, Director
Received 80,810 shares as a grant or award |
| 13 Aug 2026 |
Form 4: Simon Roberto, Director
Received 50,000 shares as a grant or award · Received 35,000 shares as a grant or award |
| 13 Aug 2026 |
Form 4: Macrae Calum Archibald, Director
Received 35,000 shares as a grant or award |
| 05 Aug 2026 | 10-Q |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially. |
| 08 Jul 2026 | SCHEDULE 13G |
| 22 Jun 2026 |
8-K: Regulation FD Disclosure
LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection |
| 03 Jun 2026 |
Form 4: Sripad Umesh, Chief Technology Officer
Received 75,000 shares as a grant or award |
| 03 Jun 2026 |
Form 3: Sripad Umesh, Chief Technology Officer
No securities owned |
| 13 May 2026 |
Form 4: Kavthekar Atul, Chief Financial Officer
Received 337,500 shares as a grant or award |
| 06 May 2026 | 10-Q |
Loading...